Why the study?
Existing models have suboptimal ability to predict stroke risk in patients with NVAF, necessitating better tools to identify high-risk individuals.
Does a novel nomogram improve the prediction of left atrial appendage thrombus and spontaneous echo contrast compared to standard risk scores in patients with non-valvular atrial fibrillation?
Population
387 patients with NVAF
Comparison
Developed nomogram vs CHA2DS2, CHA2DS2-VASc, and ATRIA scores
Design
Retrospective cohort study
Key result
A novel nomogram incorporating NT-proBNP, albumin, LAA ejection fraction, and LAA global peak longitudinal strain demonstrated superior discriminative ability for predicting LAAT/SEC compared to the CHA2DS2-VASc score (C-index 0.886 vs 0.579, p<0.05).
Authors
Loading...
May refine LAAT/SEC risk assessment in NVAF; leaves open external validation before clinical use.
Cohort (n=387)
No
Does a novel nomogram improve the prediction of left atrial appendage thrombus and spontaneous echo contrast compared to standard risk scores in patients with non-valvular atrial fibrillation?
Absolute Event Rate: 0.886% vs 0.579%
p-value: p=<0.05
A novel nomogram incorporating clinical and echocardiographic parameters significantly improves the prediction of left atrial appendage thrombus and spontaneous echo contrast in NVAF patients compared to traditional clinical risk scores.
Sun et al. (2022) conducted a cohort in Non-valvular atrial fibrillation (n=387). Nomogram (NT-proBNP, albumin, LAAEF, LAA GPLS) vs. CHA2DS2-VASc score was evaluated on Discriminative ability (C-index) for predicting left atrial appendage thrombus and spontaneous echo contrast (p=<0.05). A novel nomogram incorporating NT-proBNP, albumin, LAA ejection fraction, and LAA global peak longitudinal strain demonstrated superior discriminative ability for predicting LAAT/SEC compared to the CHA2DS2-VASc score (C-index 0.886 vs 0.579, p<0.05).